Contraindications and Cautions Of Dabigatran etexilate

  • Author:Hubei Ocean Biotech Co,.LTd
  • Release on :2016-04-25
Dabigatran etexilate is at the forefront of a new generation of oral anticoagulant direct thrombin inhibitors (DTIs), for the prevention of non-valvular atrial fibrillation patients with stroke and systemic embolism. Dabigatran etexilate provides effective, predictable and stable anticoagulant effect, while less frequent drug interactions, drug-free food interactions, without routine coagulation monitoring or dose adjustment.

AF-related stroke and SEE prevention trials excluded elevated liver enzymes> 2ULN (upper limit of normal) patients. No experience in the treatment of this subgroup of patients, it is not recommended in this population to the FDA.

As with all other anticoagulant drugs, increased risk of bleeding, dabigatran etexilate should be used with caution. In an interview with dabigatran etexilate treatment process, any part likely bleeding. If it is difficult to explain in hemoglobin and / or hematocrit or blood pressure drop occurs, attention should be looking for a bleeding site.

Hubei Ocean Biotech Co,. Ltd, a pharmaceutical products and APIs supplier, with credible service and the honest management, we have gained good reputation at domestic and abroad market. The main cause is not only for our honesty and service, but more importantly for our quality insurance about the products we offer. That's why customers choose us, our products are rest assured to buy, it is our honesty and service solved customers worries, so that we could be able to extend our market and serve more people. If you are looking for an honest and reliable Chinese supplier like us, please feel free to contact us, we sincerely looking forward to your consult.